Search

Your search keyword '"Paz A"' showing total 875 results
Start Over Author "Paz A" Journal journal of thoracic oncology
875 results on '"Paz A"'

2. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Author

Vokes, Everett E., Mornex, Francoise, Sezer, Ahmet, Cheng, Ying, Fang, Jian, Baz, David Vicente, Cil, Timucin, Adjei, Alex A., Ahn, Myung-Ju, Barlesi, Fabrice, Felip, Enriqueta, Garon, Edward B., Audhuy, Francois, Ito, Rena, Sato, Masashi, Eggleton, S. Peter, Martin, Claudio Marcelo, Reck, Martin, Robinson, Clifford G., and Paz-Ares, Luis

Published
2024
Full Text
View/download PDF

3. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Author

Peters, Solange, Paz-Ares, Luis G., Reck, Martin, Carbone, David P., Brahmer, Julie R., Borghaei, Hossein, Lu, Shun, O’Byrne, Kenneth J., John, Thomas, Ciuleanu, Tudor-Eliade, Schenker, Michael, Bernabe Caro, Reyes, Nishio, Makoto, Cobo, Manuel, Lee, Jong-Seok, Zurawski, Bogdan, Pluzanski, Adam, Aoyama, Takekazu, Tschaika, Marina, Devas, Vipul, Grootendorst, Diederik J., and Ramalingam, Suresh S.

Published
2024
Full Text
View/download PDF

4. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Author

Cho, Byoung Chul, Lee, Jong Seok, Wu, Yi-Long, Cicin, Irfan, Dols, Manuel Cobo, Ahn, Myung-Ju, Cuppens, Kristof, Veillon, Rémi, Nadal, Ernest, Dias, Josiane Mourão, Martin, Claudio, Reck, Martin, Garon, Edward B., Felip, Enriqueta, Paz-Ares, Luis, Mornex, Francoise, Vokes, Everett E., Adjei, Alex A., Robinson, Clifford, Sato, Masashi, Vugmeyster, Yulia, Machl, Andreas, Audhuy, Francois, Chaudhary, Surendra, and Barlesi, Fabrice

Published
2023
Full Text
View/download PDF

5. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Author

Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Zurawski, Bogdan, Kim, Sang-We, Mahave, Mauricio, Alexandru, Aurelia, Peters, Solange, Pluzanski, Adam, Caro, Reyes Bernabe, Linardou, Helena, Burgers, Jacobus A., Nishio, Makoto, Martinez-Marti, Alex, Azuma, Koichi, Axelrod, Rita, Paz-Ares, Luis G., Ramalingam, Suresh S., Borghaei, Hossein, O’Byrne, Kenneth J., Li, Li, Bushong, Judith, Gupta, Ravi G., Grootendorst, Diederik J., Eccles, Laura J., and Brahmer, Julie R.

Published
2023
Full Text
View/download PDF

6. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Author

Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Cobo, Manuel, Bennouna, Jaafar, Schenker, Michael, Cheng, Ying, Juan-Vidal, Oscar, Mizutani, Hideaki, Lingua, Alejo, Reyes-Cosmelli, Felipe, Reinmuth, Niels, Menezes, Juliana, Jassem, Jacek, Protsenko, Svetlana, Richardet, Eduardo, Felip, Enriqueta, Feeney, Kynan, Zurawski, Bogdan, Alexandru, Aurelia, de la Mora Jimenez, Emmanuel, Dakhil, Shaker, Lu, Shun, Reck, Martin, John, Thomas, Hu, Nan, Zhang, Xiaoqing, Sylvester, Judi, Eccles, Laura J., Grootendorst, Diederik J., Balli, David, Neely, Jaclyn, and Carbone, David P.

Published
2023
Full Text
View/download PDF

7. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Author

Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong-Seok, Gainor, Justin F., Otterson, Gregory A., Audigier-Valette, Clarisse, Ready, Neal, Schenker, Michael, Linardou, Helena, Caro, Reyes Bernabe, Provencio, Mariano, Zurawski, Bogdan, Lee, Ki Hyeong, Kim, Sang-We, Caserta, Claudia, Ramalingam, Suresh S., Spigel, David R., Brahmer, Julie R., Reck, Martin, O’Byrne, Kenneth J., Girard, Nicolas, Popat, Sanjay, Peters, Solange, Memaj, Arteid, Nathan, Faith, Aanur, Nivedita, and Borghaei, Hossein

Published
2023
Full Text
View/download PDF

8. YES1 Is a Druggable Oncogenic Target in SCLC

Author

Redin, Esther, Garrido-Martin, Eva M., Valencia, Karmele, Redrado, Miriam, Solorzano, Jose Luis, Carias, Rafael, Echepare, Mirari, Exposito, Francisco, Serrano, Diego, Ferrer, Irene, Nunez-Buiza, Angel, Garmendia, Irati, García-Pedrero, Juana M., Gurpide, Alfonso, Paz-Ares, Luis, Politi, Katerina, Montuenga, Luis M., and Calvo, Alfonso

Published
2022
Full Text
View/download PDF

9. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Author

Garassino, Marina C., Mazieres, Julien, Reck, Martin, Chouaid, Christos, Bischoff, Helge, Reinmuth, Niels, Cove-Smith, Laura, Mansy, Talal, Cortinovis, Diego, Migliorino, Maria R., Delmonte, Angelo, Sánchez, José Garcia, Chara Velarde, Luis Enrique, Bernabe, Reyes, Paz-Ares, Luis, Perez, Ignacio Diaz, Trunova, Nataliya, Foroutanpour, Kayhan, and Faivre-Finn, Corinne

Published
2022
Full Text
View/download PDF

10. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Author

Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., and Reck, Martin

Published
2022
Full Text
View/download PDF

11. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

Author

Powell, Steven F., Rodríguez-Abreu, Delvys, Langer, Corey J., Tafreshi, Ali, Paz-Ares, Luis, Kopp, Hans-Georg, Rodríguez-Cid, Jeronimo, Kowalski, Dariusz M., Cheng, Ying, Kurata, Takayasu, Awad, Mark M., Lin, Jinaxin, Zhao, Bin, Pietanza, M. Catherine, Piperdi, Bilal, and Garassino, Marina C.

Published
2021
Full Text
View/download PDF

14. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Author

Paz-Ares, Luis, Vicente, David, Tafreshi, Ali, Robinson, Andrew, Soto Parra, Hector, Mazières, Julien, Hermes, Barbara, Cicin, Irfan, Medgyasszay, Balazs, Rodríguez-Cid, Jerónimo, Okamoto, Isamu, Lee, SungSook, Ramlau, Rodryg, Vladimirov, Vladimir, Cheng, Ying, Deng, Xuan, Zhang, Ying, Bas, Tuba, Piperdi, Bilal, and Halmos, Balazs

Published
2020
Full Text
View/download PDF

16. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Author

Remon, Jordi, Passiglia, Francesco, Ahn, Myung-Ju, Barlesi, Fabrice, Forde, Patrick M., Garon, Edward B., Gettinger, Scott, Goldberg, Sarah B., Herbst, Roy S., Horn, Leora, Kubota, Kaoru, Lu, Shun, Mezquita, Laura, Paz-Ares, Luis, Popat, Sanjay, Schalper, Kurt A., Skoulidis, Ferdinandos, Reck, Martin, Adjei, Alex A., and Scagliotti, Giorgio V.

Published
2020
Full Text
View/download PDF

17. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Author

Travis, William D., Dacic, Sanja, Wistuba, Ignacio, Sholl, Lynette, Adusumilli, Prasad, Bubendorf, Lukas, Bunn, Paul, Cascone, Tina, Chaft, Jamie, Chen, Gang, Chou, Teh-Ying, Cooper, Wendy, Erasmus, Jeremy J., Ferreira, Carlos Gil, Goo, Jin-Mo, Heymach, John, Hirsch, Fred R., Horinouchi, Hidehito, Kerr, Keith, Kris, Mark, Jain, Deepali, Kim, Young T., Lopez-Rios, Fernando, Lu, Shun, Mitsudomi, Tetsuya, Moreira, Andre, Motoi, Noriko, Nicholson, Andrew G., Oliveira, Ricardo, Papotti, Mauro, Pastorino, Ugo, Paz-Ares, Luis, Pelosi, Giuseppe, Poleri, Claudia, Provencio, Mariano, Roden, Anja C., Scagliotti, Giorgio, Swisher, Stephen G., Thunnissen, Erik, Tsao, Ming S., Vansteenkiste, Johan, Weder, Walter, and Yatabe, Yasushi

Published
2020
Full Text
View/download PDF

18. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Author

Huber, Rudolf M., Hansen, Karin H., Paz-Ares Rodríguez, Luis, West, Howard L., Reckamp, Karen L., Leighl, Natasha B., Tiseo, Marcello, Smit, Egbert F., Kim, Dong-Wan, Gettinger, Scott N., Hochmair, Maximilian J., Kim, Sang-We, Langer, Corey J., Ahn, Myung-Ju, Kim, Edward S., Kerstein, David, Groen, Harry J.M., and Camidge, D. Ross

Published
2020
Full Text
View/download PDF

19. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Author

Dingemans, Anne-Marie C., Hendriks, Lizza E.L., Berghmans, Thierry, Levy, Antonin, Hasan, Baktiar, Faivre-Finn, Corinne, Giaj-Levra, Matteo, Giaj-Levra, Niccolò, Girard, Nicolas, Greillier, Laurent, Lantuéjoul, Sylvie, Edwards, John, O’Brien, Mary, Reck, Martin, Smit, Egbert F., Van Schil, Paul, Postmus, Pieter E., Ramella, Sara, Lievens, Yolande, Gaga, Mina, Peled, Nir, Scagliotti, Giorgio V., Senan, Suresh, Paz-Ares, Luiz, Guckenberger, Matthias, McDonald, Fiona, Ekman, Simon, Cufer, Tanja, Gietema, Hester, Infante, Maurizio, Dziadziuszko, Rafal, Peters, Solange, Porta, Ramon Rami, Vansteenkiste, Johan, Dooms, Christophe, de Ruysscher, Dirk, Besse, Benjamin, and Novello, Silvia

Published
2019
Full Text
View/download PDF

20. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Author

Conde, Esther, Hernandez, Susana, Martinez, Rebeca, Angulo, Barbara, De Castro, Javier, Collazo-Lorduy, Ana, Jimenez, Beatriz, Muriel, Alfonso, Mate, Jose Luis, Moran, Teresa, Aranda, Ignacio, Massuti, Bartomeu, Rojo, Federico, Domine, Manuel, Sansano, Irene, Garcia, Felip, Felip, Enriqueta, Mancheño, Nuria, Juan, Oscar, Sanz, Julian, Gonzalez-Larriba, Jose Luis, Atienza-Cuevas, Lidia, Arriola-Arellano, Esperanza, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Camacho, Carmen, Rodriguez-Abreu, Delvys, Teixido, Cristina, Reguart, Noemi, Gonzalez-Piñeiro, Ana, Lazaro-Quintela, Martin, Lozano, Maria Dolores, Gurpide, Alfonso, Gomez-Roman, Javier, Lopez-Brea, Marta, Pijuan, Lara, Salido, Marta, Arriola, Edurne, Company, Amparo, Insa, Amelia, Esteban-Rodriguez, Isabel, Saiz, Monica, Azkona, Eider, Alvarez, Ramiro, Artal, Angel, Plaza, Maria Luz, Aguiar, David, Enguita, Ana Belen, Benito, Amparo, Paz-Ares, Luis, Garrido, Pilar, and Lopez-Rios, Fernando

Published
2019
Full Text
View/download PDF

22. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Author

Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Oscar Juan-Vidal, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, Juliana Menezes, Jacek Jassem, Svetlana Protsenko, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Zurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker Dakhil, Shun Lu, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone, Institut Català de la Salut, [Paz-Ares LG] Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain. [Ciuleanu TE] Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. [Cobo M] Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Bennouna J] Department of Pneumology, Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France. [Schenker M] Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania. [Cheng Y] Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin, People’s Republic of China. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Pulmonary and Respiratory Medicine, Otros calificadores::/uso terapéutico [Otros calificadores], terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Quimioteràpia combinada, Oncology, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Avaluació de resultats (Assistència sanitària), Other subheadings::/therapeutic use [Other subheadings], Pulmons - Càncer - Tractament
Abstract

Non–small cell lung cancer; Brain metastases; Somatic mutations Càncer de pulmó de cèl·lules no petites; Metàstasis cerebrals; Mutacions somàtiques Cáncer de pulmón de células no pequeñas; Metástasis cerebrales; Mutaciones somáticas Introduction In the phase 3 CheckMate 9LA study, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy alone. We report updated efficacy and safety (≥3 y of follow-up), clinical outcomes in patients with baseline brain metastases, and exploratory somatic mutation analyses. Methods Adults with stage IV or recurrent NSCLC, no known sensitizing EGFR or ALK alterations, and Eastern Cooperative Oncology Group performance status less than or equal to 1 were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with chemotherapy (two cycles) or chemotherapy alone (four cycles). Assessments included OS, progression-free survival (PFS), and objective response rate. Exploratory analyses included systemic and intracranial efficacy in patients with or without baseline brain metastases, in addition to OS and PFS by KRAS, TP53, STK11, and KEAP1 somatic mutation status in patients with nonsquamous NSCLC. Results With a minimum follow-up of 36.1 months, nivolumab plus ipilimumab with chemotherapy continued to prolong OS versus chemotherapy alone in the intent-to-treat population (median [hazard ratio; 95% confidence interval] OS: 15.8 versus 11.0 mo [0.74; 0.62–0.87]; 3-y OS: 27% versus 19%). Efficacy outcomes were improved in patients with pretreated baseline brain metastases (median [hazard ratio; 95% confidence interval] OS: 19.3 versus 6.8 mo [0.45; 0.29–0.70]; systemic PFS: 9.7 versus 4.1 mo [0.44; 0.28–0.69]; intracranial PFS: 11.4 versus 4.6 mo [0.42; 0.26–0.68]). A trend of OS benefit was observed in patients treated with nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone, despite KRAS, TP53, and STK11 tumor mutations. Extended follow-up revealed no new safety signals. Conclusions With a 3-year minimum follow-up, nivolumab plus ipilimumab with two cycles of chemotherapy continued to have long-term, durable efficacy versus chemotherapy alone; a manageable safety profile; and survival benefit in patients with or without baseline brain metastases or select somatic mutations, further supporting the regimen as first-line treatment for patients with metastatic NSCLC. This study was supported by Bristol Myers Squibb (Princeton, NJ).

Published
2023

24. OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

Author

Ramalingam, S.S., primary, Ciuleanu, T.-E., additional, Bernabe Caro, R., additional, Nishio, M., additional, Mizutani, H., additional, Lee, J.-S., additional, Audigier-Valette, C., additional, Sangha, R., additional, Urban, L., additional, Burgers, J.A., additional, Pluzanski, A., additional, Lee, K.H., additional, Zurawski, B., additional, Schenker, M., additional, Peters, S., additional, Paz-Ares, L.G., additional, Borghaei, H., additional, O’Byrne, K.J., additional, Brahmer, J.R., additional, Gupta, R.G., additional, Bushong, J., additional, Li, L., additional, Yuan, Y., additional, Blum, S.I., additional, and Reck, M., additional

Published
2023
Full Text
View/download PDF

25. P1.21-07 Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer

Author

Baena, J., primary, Calles, A., additional, Aguado, C., additional, Antoñanzas, M., additional, Lage, Y., additional, Sereno, M., additional, Mielgo, X., additional, Lopez, A., additional, Cervera, R., additional, Cabezón-Gutierrez, L., additional, Rubio, J., additional, Sanchez-Becerra, M.V., additional, Molero-Abraham, M., additional, Peressini, M., additional, Ruiz de Garibay, G., additional, Fernández-Luna, C., additional, Adradas, V., additional, Herrera, M., additional, Cabo, H., additional, Alvarez, R., additional, Garrido, P., additional, Gonzalez-Larriba, J.L., additional, López-Ríos, F., additional, Conde, E., additional, Paz-Ares, L., additional, and Zugazagoitia, J., additional

Published
2023
Full Text
View/download PDF

26. P1.23-08 Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer

Author

Bote de Cabo, H., primary, Siringo, M., additional, García-Lorenzo, E., additional, Castelo, A., additional, Conde, E., additional, Hernández, S., additional, López-Ríos Moreno, F., additional, Herrera, M., additional, Baena, J., additional, Ruano-Domínguez, Y., additional, Enguita, A.B., additional, Pérez, U., additional, Paz-Ares, L., additional, and Zugazagoitia, J., additional

Published
2023
Full Text
View/download PDF

27. P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

Author

Reck, M., primary, Worthy, G., additional, Yuan, Y., additional, Penrod, J.R., additional, Lawrance, R., additional, Taylor, F., additional, Blum, S.I., additional, Moisei, A., additional, Lee, A., additional, Ciuleanu, T.-E., additional, Pluzanski, A., additional, Lee, J.-S., additional, Ramalingam, S., additional, Borghaei, H., additional, O’Byrne, K., additional, Paz-Ares, L., additional, Li, L., additional, Gupta, R.G., additional, Bushong, J., additional, and Brahmer, J., additional

Published
2023
Full Text
View/download PDF

30. P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial

Author

Navarro, A., primary, Smit, E., additional, Carcereny, E., additional, Gutierrez, V., additional, Mavroudis, D., additional, Reinmuth, N., additional, Bustin, F., additional, Lopez-Vilariño, J.A., additional, Gómez, J., additional, Kahatt, C., additional, Zeaiter, A., additional, Cousin, S., additional, Ciuleanu, T.E., additional, Lungulescu, D., additional, Robev, B., additional, and Paz-Ares, L., additional

Published
2023
Full Text
View/download PDF

32. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Author

Vokes, Everett E., primary, Mornex, Francoise, additional, Sezer, Ahmet, additional, Cheng, Ying, additional, Fang, Jian, additional, Baz, David Vicente, additional, Cil, Timucin, additional, Adjei, Alex A., additional, Ahn, Myung-Ju, additional, Barlesi, Fabrice, additional, Felip, Enriqueta, additional, Garon, Edward B., additional, Audhuy, Francois, additional, Ito, Rena, additional, Sato, Masashi, additional, Eggleton, S. Peter, additional, Martin, Claudio Marcelo, additional, Reck, Martin, additional, Robinson, Clifford G., additional, and Paz-Ares, Luis, additional

Published
2023
Full Text
View/download PDF

36. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1–high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial

Author

Cho, Byoung Chul, primary, Lee, Jong Seok, additional, Wu, Yi-Long, additional, Cicin, Irfan, additional, Dols, Manuel Cobo, additional, Ahn, Myung-Ju, additional, Cuppens, Kristof, additional, Veillon, Rémi, additional, Nadal, Ernest, additional, Dias, Josiane Mourão, additional, Martin, Claudio, additional, Reck, Martin, additional, Garon, Edward B., additional, Felip, Enriqueta, additional, Paz-Ares, Luis, additional, Mornex, Francoise, additional, Vokes, Everett E., additional, Adjei, Alex A., additional, Robinson, Clifford, additional, Sato, Masashi, additional, Vugmeyster, Yulia, additional, Machl, Andreas, additional, Audhuy, Francois, additional, Chaudhary, Surendra, additional, and Barlesi, Fabrice, additional

Published
2023
Full Text
View/download PDF

37. Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1

Author

Reck, Martin, primary, Ciuleanu, Tudor-Eliade, additional, Lee, Jong-Seok, additional, Schenker, Michael, additional, Zurawski, Bogdan, additional, Kim, Sang-We, additional, Mahave, Mauricio, additional, Alexandru, Aurelia, additional, Peters, Solange, additional, Pluzanski, Adam, additional, Caro, Reyes Bernabe, additional, Linardou, Helena, additional, Burgers, Jacobus A., additional, Nishio, Makoto, additional, Martinez-Marti, Alex, additional, Azuma, Koichi, additional, Axelrod, Rita, additional, Paz-Ares, Luis G., additional, Ramalingam, Suresh S., additional, Borghaei, Hossein, additional, O’Byrne, Kenneth J., additional, Li, Li, additional, Bushong, Judith, additional, Gupta, Ravi G., additional, Grootendorst, Diederik J., additional, Eccles, Laura J., additional, and Brahmer, Julie R., additional

Published
2023
Full Text
View/download PDF

38. 165P SCLC subtypes are associated with distinct dinicopathological features and outcomes: A biomarker analysis from the CANTABRICO study

Author

Rocha, P., primary, Sanchez, I., additional, Pinto, L. Masfarre, additional, Giner, M., additional, Gorro, N. Navarro, additional, Hoyo, A. Rios, additional, Garcia, A. Taus, additional, Pérez-Buira, S., additional, Torres-Fernandez, É., additional, Clave, S., additional, Paricio, B. Bellosillo, additional, Rojo, F., additional, Paz-Ares, L., additional, Cubells, C. Martí, additional, de la Rosa, C. Aguado, additional, Casado, M.D. Isla, additional, Garcia-Campelo, R., additional, Baez, L., additional, Mellén, Á. Callejo, additional, and Arriola, E., additional

Published
2023
Full Text
View/download PDF

39. OA01.04 First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update

Author

Carbone, D.P., primary, Paz-Ares, L.G., additional, Ciuleanu, T.E., additional, Cobo-Dols, M., additional, Bennouna, J., additional, Cheng, Y., additional, Mizutani, H., additional, Lingua, A., additional, Reyes, F., additional, Reinmuth, N., additional, Menezes, J., additional, Jassem, J., additional, Protsenko, S., additional, Feeney, K., additional, de la Mora Jimenez, E., additional, Lu, S., additional, John, T., additional, Zhang, X., additional, Hu, N., additional, and Reck, M., additional

Published
2023
Full Text
View/download PDF

40. PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227

Author

Borghaei, H., primary, Brahmer, J.R., additional, Lee, J.-S., additional, Ciuleanu, T.-E., additional, Bernabe Caro, R., additional, Nishio, M., additional, Urban, L., additional, Audigier-Valette, C., additional, Lupinacci, L., additional, Sangha, R., additional, Paz-Ares, L.G., additional, Reck, M., additional, John O’Byrne, K., additional, Gupta, R.G., additional, Bushong, J., additional, Li, L., additional, Blum, S.I., additional, Eccles, L., additional, and Ramalingam, S.S., additional

Published
2023
Full Text
View/download PDF

41. OA01.08 Clinical Response to Tepotinib According to Circulating Tumor (ct)DNA Biomarkers in Patients with Advanced/Metastatic NSCLC with High-level MET Amplification (METamp) Detected by Liquid Biopsy (LBx)

Author

Le, X., primary, Paz-Ares, L.G., additional, Van Meerbeeck, J., additional, Viteri, S., additional, Cabrera-Galvez, C., additional, Baz, D.V., additional, Kim, Y.-C., additional, Kang, J.-H., additional, Stroh, C., additional, Juraeva, D., additional, Bruns, R., additional, Otto, G., additional, Johne, A., additional, and Paik, P.K., additional

Published
2023
Full Text
View/download PDF

42. Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1

Author

Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martinez-Marti, Koichi Azuma, Rita Axelrod, Luis G. Paz-Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O’Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, and Julie R. Brahmer

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2023

Catalog

Books, media, physical & digital resources
See catalog results